PARIS – The French government needs guarantees from drugmaker Sanofi (NASDAQ: SNY) that production of its popular Doliprane painkiller will […]
France Seeks Job Guarantees from Sanofi Over Doliprane Painkiller Production Read More »
Sanofi (NASDAQ: SNY) is closing in on a deal to sell its consumer health unit for about 15 billion euros
Sanofi (NASDAQ: SNY) Nears $16 Billion Sale of Consumer Health Unit to CD&R, Source Says Read More »
GSK (NYSE: GSK), Sanofi (NASDAQ: SNY), and CSL Ltd have secured $72 million from the U.S. government to ramp up
Sanofi, GSK, CSL Secure $72 Million Funding to Expand US Bird Flu Vaccine Supply Read More »
On Friday, Recordati, the Italian pharma group, said it would buy from Sanofi (NASDAQ: SNY) the global rights to a
Recordati and Sanofi Shares Rise Following $825 Million Drug Rights Deal Read More »
Sanofi (NASDAQ: SNY) has received two separate bids from private equity firms for its consumer health unit, which could be
NEW YORK – Sanofi’s (NASDAQ: SNY) chief executive, Paul Hudson, said in an interview on Monday that the company is
Sanofi (NASDAQ: SNY) CEO Believes New Drugs Will Drive Company Growth Read More »
On Friday, the U.S. Food and Drug Administration said it has approved the use of a drug combination along with
FRANKFURT – On Friday, Sanofi (NASDAQ: SNY) said that its multiple sclerosis drug candidate was shown to delay the worsening
Sanofi (NASDAQ: SNY) Reports Key Milestone in Multiple Sclerosis Drug Development Read More »
Sanofi’s (NASDAQ: SNY) most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat
Sanofi’s (NASDAQ: SNY) Mixed Fortunes in MS Drug Trials Has Market Focus on Win Read More »
Copyright © 2024 abbonews.com
